Endonovo Therapeutics (Endonovo Therapeutics) EPS (Basic) : $0.04 (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics EPS (Basic)?

Endonovo Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.04.

Endonovo Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01.

Endonovo Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Endonovo Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 87.50% per year. The lowest was -162.00% per year. And the median was 3.40% per year.

Endonovo Therapeutics EPS (Basic) Historical Data

The historical data trend for Endonovo Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics EPS (Basic) Chart

Endonovo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-24.83

-0.03

-0.05

-0.13

0.03

Endonovo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.08	0.03	0.01	-	-

Endonovo Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Endonovo Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(6.925	-	0)	/	276.355
	=	0.03

Endonovo Therapeutics's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.603	-	0)	/	276.355
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04

Endonovo Therapeutics (OTCPK:ENDV) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Endonovo Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367

Website

https://www.endonovo.com

Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.

Executives

Alan Brian Collier	director, 10 percent owner, officer: CEO	6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann	10 percent owner, officer: President	6320 CANOGA AVENUE, WOODLAND HILLS CA 91367